Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CHIMERIC MONOCLONAL-ANTIBODY' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 154 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Bondeson, J; Maini, RN
      Tumour necrosis factor as a therapeutic target in rheumatoid arthritis andother chronic inflammatory diseases: The clinical experience with infliximab (Remicade (TM))

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    2. Pearce, GJ; Chikanza, IC
      Targeting tumour necrosis factor in the treatment of rheumatoid arthritis

      BIODRUGS
    3. Mahadevan, U; Sandborn, WJ
      Infliximab for the treatment of orofacial Crohn's disease

      INFLAMMATORY BOWEL DISEASES
    4. Ellman, MH; Hanauer, S; Sitrin, M; Cohen, R
      Crohn's disease arthritis treated with infliximab: An open trial in four patients

      JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
    5. Serrano, MS; Schmidt-Sommerfeld, E; Kilbaugh, TJ; Brown, RF; Udall, JN; Mannick, EE
      Use of infliximab in pediatric patients with inflammatory bowel disease

      ANNALS OF PHARMACOTHERAPY
    6. Kim, ES; Khuri, FR; Herbst, RS
      Epidermal growth factor receptor biology (IMC-C225)

      CURRENT OPINION IN ONCOLOGY
    7. Tschoep, K; Hartmann, G; Jox, R; Thompson, S; Eigler, A; Krug, A; Erhardt, S; Adams, G; Endres, S; Delius, M
      Shock waves: a novel method for cytoplasmic delivery of antisense oligonucleotides

      JOURNAL OF MOLECULAR MEDICINE-JMM
    8. Keystone, EC
      Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis

      RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
    9. LaDuca, JR; Gaspari, AA
      Targeting tumor necrosis factor alpha - New drugs used to modulate inflammatory diseases

      DERMATOLOGIC CLINICS
    10. Feldmann, M; Maini, RN
      Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

      ANNUAL REVIEW OF IMMUNOLOGY
    11. Kalofonos, HP; Karamouzis, MV; Epenetos, AA
      Radioimmunoscintigraphy in patients with ovarian cancer

      ACTA ONCOLOGICA
    12. Baldassano, RN
      Surpassing conventional therapies: The role of biologic therapy

      JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
    13. Schreiber, S; Campieri, M; Colombel, JF; van Deventer, SJH; Feagan, B; Fedorak, R; Forbes, A; Gassull, M; Gendre, JP; van Hogezand, RA; Lofberg, R; Modigliani, R; Pallone, F; Petritsch, W; Prantera, C; Rampton, D; Seibold, F; Vatn, M; Zeitz, M; Rutgeerts, P
      Use of anti-tumour necrosis factor agents in inflammatory bowel disease - European guidelines for 2001-2003

      INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
    14. Visser, GW; Klok, RP; Gebbinck, JWK; ter Linden, T; van Dongen, GA; Molthoff, CF
      Optimal quality I-131-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN

      JOURNAL OF NUCLEAR MEDICINE
    15. Kamradt, T; Mitchison, NA
      Advances in immunology: Tolerance and autoimmunity.

      NEW ENGLAND JOURNAL OF MEDICINE
    16. Su, CYG; Judge, TA; Lichtenstein, GR
      The role of biological therapy in inflammatory bowel disease

      DRUGS OF TODAY
    17. Xue, CB; Voss, ME; Nelson, DJ; Duan, JJW; Cherney, RJ; Jacobson, IC; He, XH; Roderick, J; Chen, LH; Corbett, RL; Wang, L; Meyer, DT; Kennedy, K; DeGrado, WF; Hardman, KD; Teleha, CA; Jaffee, BD; Liu, RQ; Copeland, RA; Covington, MB; Christ, DD; Trzaskos, JM; Newton, RC; Magolda, RL; Wexler, RR; Decicco, CP
      Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro andin vivo

      JOURNAL OF MEDICINAL CHEMISTRY
    18. Hansen, PR; Chew, M; Zhou, J; Daugherty, A; Heegaard, N; Jensen, P; Mouritsen, S
      Freunds adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNF alpha confers no additional benefit

      ATHEROSCLEROSIS
    19. Gause, A; Manger, B; Kalden, JR; Burmester, GR
      Treatment of inflammatory rheumatic diseases - From a standard into the future

      INTERNIST
    20. El Desoky, ES
      Pharmacotherapy of rheumatoid arthritis: An overview

      CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    21. Ogilvie, ALJ; Antoni, C; Dechant, C; Manger, B; Kalden, JR; Schuler, G; Luftl, M
      Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

      BRITISH JOURNAL OF DERMATOLOGY
    22. Smith, JR; Levinson, RD; Holland, GN; Jabs, DA; Robinson, MR; Whitcup, SM; Rosenbaum, JT
      Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease

      ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
    23. Robinson, WH; Genovese, MC; Moreland, LW
      Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism - By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

      ARTHRITIS AND RHEUMATISM
    24. Blam, ME; Stein, RB; Lichtenstein, GR
      Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives

      AMERICAN JOURNAL OF GASTROENTEROLOGY
    25. Maiuri, L; Ciacci, C; Vacca, L; Ricciardelli, I; Auricchio, S; Quaratino, S; Londei, M
      IL-15 drives the specific migration of CD94+and TCR-gamma delta+ intraepithelial lymphocytes in organ cultures of treated celiac patients

      AMERICAN JOURNAL OF GASTROENTEROLOGY
    26. Lorenz, HM; Geiler, T
      New strategies in the immunotherapy of autoimmune diseaes

      DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
    27. D'Haens, G
      Infliximab (Remicade (R)): the magic bullet for Crohn's disease?

      DIGESTIVE AND LIVER DISEASE
    28. Standiford, TJ
      Anti-inflammatory cytokines and cytokine antagonists

      CURRENT PHARMACEUTICAL DESIGN
    29. Van Assche, G; Rutgeerts, P
      Anti-TNF agents in Crohn's disease

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    30. Bondeson, J; Feldmann, M; Maini, RN
      TNF as a therapeutic target

      IMMUNOLOGIST
    31. Chang, TW
      The pharmacological basis of anti-IgE therapy

      NATURE BIOTECHNOLOGY
    32. Rutgeerts, P
      Infliximab is the drug we have been waiting for in Crohn's disease

      INFLAMMATORY BOWEL DISEASES
    33. Bernstein, CN
      Is infliximab the drug we have been waiting for in Crohn's disease? Commentary

      INFLAMMATORY BOWEL DISEASES
    34. De Keyser, F; Van Damme, N; De Vos, M; Mielants, H; Veys, EM
      Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation

      INFLAMMATION RESEARCH
    35. Fujiwara, N; Fujita, H; Iwai, K; Kurimoto, A; Murata, S; Kawakami, H
      Synthesis and bioactivities of novel piperidylpyrimidine derivatives: Inhibitors of tumor necrosis factor-alpha production

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    36. Illei, GG; Lipsky, PE
      Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases

      CURRENT OPINION IN IMMUNOLOGY
    37. Milpied, N; Vasseur, B; Parquet, N; Garnier, JL; Antoine, C; Quartier, P; Carret, AS; Bouscary, D; Faye, A; Bourbigot, B; Reguerre, Y; Stoppa, AM; Bourquard, P; de Ligny, BH; Dubief, F; Mathieu-Boue, A; Leblond, V
      Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients

      ANNALS OF ONCOLOGY
    38. Foran, JM; Cunningham, D; Coiffier, B; Solal-Celigny, P; Reyes, F; Ghielmini, M; Johnson, PWM; Gisselbrecht, C; Bradburn, M; Matthews, J; Lister, TA
      Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response

      ANNALS OF ONCOLOGY
    39. Ayala, JM; Goyal, S; Liverton, NJ; Claremon, DA; O'Keefe, SJ; Hanlon, WA
      Serum-induced monocyte differentiation and monocyte chemotaxis are regulated by the p38 MAP kinase signal transduction pathway

      JOURNAL OF LEUKOCYTE BIOLOGY
    40. Regimbeau, JM; Panis, Y; De Parades, V; Marteau, P; Valleur, P
      Anoperineal Crohn's disease

      GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
    41. Heuschkel, RB
      New immunologic treatments for inflammatory bowel disease

      CURRENT OPINION IN GASTROENTEROLOGY
    42. Fautrel, B; Cherin, P
      Interest of anti-TNF-alpha treatment in inflammatory and infectious diseases.

      REVUE DE MEDECINE INTERNE
    43. Regueiro, MD
      The colon, inflammatory bowel disease, & infectious diseases - Update in medical treatment of Crohn's disease

      JOURNAL OF CLINICAL GASTROENTEROLOGY
    44. Scholmerich, J
      Future developments in diagnosis and treatment of inflammatory bowel disease

      HEPATO-GASTROENTEROLOGY
    45. van Zanten-Przybysz, I; Molthoff, CF; Roos, JC; Plaizier, MA; Visser, GW; Pijpers, R; Kenemans, P; Verheijen, RH
      Radioimmunotherapy with intravenously administered I-131-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer

      JOURNAL OF NUCLEAR MEDICINE
    46. Hornick, JL; Sharifi, J; Khawli, LA; Hu, PS; Bai, WG; Alauddin, MM; Mizokami, MM; Epstein, AL
      Single amino acid substitution in the Fc region of chimeric TNT-3 antibodyaccelerates clearance and improves immunoscintigraphy of solid tumors

      JOURNAL OF NUCLEAR MEDICINE
    47. Lipsky, PE; van der Heijde, DMFM; St Clair, EW; Furst, DE; Breedveld, FC; Kalden, JR; Smolen, JS; Weisman, M; Emery, P; Feldmann, M; Harriman, GR; Maini, RN
      Infliximab and methotrexate in the treatment of rheumatoid arthritis

      NEW ENGLAND JOURNAL OF MEDICINE
    48. Rutgeerts, P; Baert, F
      Novel therapies for Crohn's disease

      DRUGS OF TODAY
    49. Hartmann, G; Bidlingmaier, C; Siegmund, B; Albrich, S; Schulze, J; Tschoep, K; Eigler, A; Lehr, HA; Endres, S
      Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    50. Hyams, JS; Markowitz, J; Wyllie, R
      Use of infliximab in the treatment of Crohn's disease in children and adolescents

      JOURNAL OF PEDIATRICS
    51. Hill, DB; Barve, S; Joshi-Barve, S; McClain, C
      Increased monocyte nuclear factor-kappa B activation and tumor necrosis factor production in alcoholic hepatitis

      JOURNAL OF LABORATORY AND CLINICAL MEDICINE
    52. Infante-Duarte, C; Horton, HF; Byrne, MC; Kamradt, T
      Microbial lipopeptides induce the production of IL-17 in Th cells

      JOURNAL OF IMMUNOLOGY
    53. Croxford, JL; Triantaphyllopoulos, KA; Neve, RM; Feldmann, M; Chernajovsky, Y; Baker, D
      Gene therapy for chronic relapsing experimental allergic encephalomyelitisusing cells expressing a novel soluble p75 dimeric TNF receptor

      JOURNAL OF IMMUNOLOGY
    54. Segain, JP; de la Bletiere, DR; Bourreille, A; Leray, V; Gervois, N; Rosales, C; Ferrier, L; Bonnet, C; Blottiere, HM; Galmiche, JP
      Butyrate inhibits inflammatory responses through NF kappa B inhibition: implications for Crohn's disease

      GUT
    55. Sands, BE
      Therapy of inflammatory bowel disease

      GASTROENTEROLOGY
    56. Bolger, AP; Anker, SD
      Tumour necrosis factor in chronic heart failure - A peripheral view on pathogenesis, clinical manifestations and therapeutic implications

      DRUGS
    57. Markham, A; Lamb, HM
      Infliximab - A review of its use in the management of rheumatoid arthritis

      DRUGS
    58. Hawkins, J; Zheng, S; Frantz, B; LoGrasso, P
      p38 map kinase substrate specificity differs greatly for protein and peptide substrates

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    59. Schumann, J; Wolf, D; Pahl, A; Brune, K; Papadopoulos, T; van Rooijen, N; Tiegs, G
      Importance of Kupffer cells for T-cell-dependent liver injury in mice

      AMERICAN JOURNAL OF PATHOLOGY
    60. Cohen, RD; Tsang, JF; Hanauer, SB
      Infliximab in Crohn's disease: First anniversary clinical experience

      AMERICAN JOURNAL OF GASTROENTEROLOGY
    61. Taylor, PC
      Antibodies for inflammatory disease - Cytokines

      DIAGNOSTIC AND THERAPEUTIC ANTIBODIES
    62. Feldmann, M; Maini, RN
      The role of cytokines in the pathogenesis of rheumatoid arthritis

      RHEUMATOLOGY
    63. D'Haens, GR
      Infliximab (Remicade (TM)), a new biological treatment for Crohn's disease

      ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
    64. Schrand, LM
      Recent additions to the brewing biotechnology armamentarium: A critical assessment

      FORMULARY
    65. Heller, T; James, SP; Drachenberg, C; Hernandez, C; Darwin, PE
      Treatment of severe esophageal Crohn's disease with infliximab

      INFLAMMATORY BOWEL DISEASES
    66. Sandborn, WJ; Hanauer, SB
      Antitumor necrosis factor therapy for inflammatory bowel disease: A reviewof agents, pharmacology, clinical results, and safety

      INFLAMMATORY BOWEL DISEASES
    67. Kamigaki, T; Ajiki, T; Yamamoto, M; Kuroda, Y
      Enhancement of tumor uptakes by stabilized Fab homo-oligomers of a chimeric monoclonal antibody against carcinoembryonic antigen

      INTERNATIONAL JOURNAL OF ONCOLOGY
    68. Dinarello, CA
      Blocking IL-1 and TNF

      JOURNAL OF ENDOTOXIN RESEARCH
    69. Cherney, RJ; Wang, L; Meyer, DT; Xue, CB; Arner, EC; Copeland, RA; Covington, MB; Hardman, KD; Wasserman, ZR; Jaffee, BD; Decicco, CP
      Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    70. Sawada, T; Nishihara, T; Yamamoto, A; Teraoka, H; Yamashita, Y; Okamura, T; Ochi, H; Ho, JJL; Kim, Y; Hirakawa, K
      Preoperative clinical radioimmunodetection of pancreatic cancer by In-111-labeled chimeric monoclonal antibody Nd2

      JAPANESE JOURNAL OF CANCER RESEARCH
    71. Sands, BE
      Novel therapies for inflammatory bowel disease

      GASTROENTEROLOGY CLINICS OF NORTH AMERICA
    72. Desreumaux, P; Meresse, B; Cortot, A; Colombel, JF
      Cytokines and anti-cytokines in inflammatory bowel disease

      GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
    73. Boehme, MWJ; Gao, IK
      Present importance of direct immunologically based intervention strategiesusing anticytokines in rheumatoid arthritis

      ZEITSCHRIFT FUR RHEUMATOLOGIE
    74. Baert, FJ; Rutgeerts, PR
      Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications

      INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
    75. Blackwell, JM
      Tumour necrosis factor alpha and mucocutaneous leishmaniasis

      PARASITOLOGY TODAY
    76. Waksal, HW
      Role of an anti-epidermal growth factor receptor in treating cancer

      CANCER AND METASTASIS REVIEWS
    77. Huang, SM; Harari, PM
      Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results

      INVESTIGATIONAL NEW DRUGS
    78. Pena, LR; Hill, DB; McClain, CJ
      Treatment with glutathione precursor decreases cytokine activity

      JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
    79. Hodgson, H
      Prospects of new therapeutic approaches for Crohn's disease

      LANCET
    80. Schreiber, S; Nikolaus, S; Hampe, J; Hamling, J; Koop, I; Groessner, B; Lochs, H; Raedler, A
      Tumour necrosis factor a and interleukin 1 beta in relapse of Crohn's disease

      LANCET
    81. Moreland, LW
      The role of cytokines in rheumatoid arthritis: Inhibition of cytokines in therapeutic trials

      DRUGS OF TODAY
    82. Newton, RC; Decicco, CP
      Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha

      JOURNAL OF MEDICINAL CHEMISTRY
    83. Liverton, NJ; Butcher, JW; Claiborne, CF; Claremon, DA; Libby, BE; Nguyen, KT; Pitzenberger, SM; Selnick, HG; Smith, GR; Tebben, A; Vacca, JP; Varga, SL; Agarwal, L; Dancheck, K; Forsyth, AJ; Fletcher, DS; Frantz, B; Hanlon, WA; Harper, CF; Hofsess, SJ; Kostura, M; Lin, J; Luell, S; O'Neill, EA; Orevillo, CJ; Pang, M; Parsons, J; Rolando, A; Sahly, Y; Visco, DM; O'Keefe, SJ
      Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase

      JOURNAL OF MEDICINAL CHEMISTRY
    84. Charles, P; Elliott, MJ; Davis, D; Potter, A; Kalden, JR; Antoni, C; Breedveld, FC; Smolen, JS; Eberl, G; deWoody, K; Feldmann, M; Maini, RN
      Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis

      JOURNAL OF IMMUNOLOGY
    85. Bondeson, J; Browne, KA; Brennan, FM; Foxwell, BMJ; Feldmann, M
      Selective regulation of cytokine induction by adenoviral gene transfer of I kappa B alpha into human macrophages: Lipopolysaccharide-induced, but notzymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear Factor-kappa B independent

      JOURNAL OF IMMUNOLOGY
    86. Eysselein, VE
      Proteolytic release of membrane bound intercellular regulators

      GUT
    87. Manns, MP; Jaeckel, E
      Searching for the needle in the haystack: Another candidate needle in autoimmune hepatitis?

      GASTROENTEROLOGY
    88. Kobayashi, H; Le, N; Kim, IS; Kim, MG; Pie, JE; Drumm, D; Paik, DS; Waldmann, TA; Paik, CH; Carrasquillo, JA
      The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points

      CANCER RESEARCH
    89. Nurden, P; Poujol, C; Durrieu-Jais, C; Winckler, J; Combrie, R; Macchi, L; Bihour, C; Wagner, C; Jordan, R; Nurden, AT
      Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): Flow and endocytic mechanisms contribute to the transport

      BLOOD
    90. Glaser, KB; Pease, L; Li, JL; Morgan, DW
      Enhancement of the surface expression of tumor necrosis factor alpha (TNF alpha) but not the p55 TNF alpha receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors

      BIOCHEMICAL PHARMACOLOGY
    91. Harriman, G; Harper, LK; Schaible, TF
      Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF alpha treatment

      ANNALS OF THE RHEUMATIC DISEASES
    92. van Deventer, SJH
      Anti-TNF antibody treatment of Crohn's disease

      ANNALS OF THE RHEUMATIC DISEASES
    93. Rutgeerts, P; Baert, F
      New strategies in the management of inflammatory bowel disease.

      ACTA CLINICA BELGICA
    94. MURTHY S; FLANIGAN A; OSBORNE BJ; MURTHY NS
      INFLAMMATORY BOWEL DISEASES - A NEW-WAVE OF THERAPY

      Expert opinion on therapeutic patents
    95. CORCORAN AE; SCALLON BJ; TRINH H; CHERNAJOVSKY Y; GHRAYEB J; FELDMANN M
      MINIMAL TUMOR-NECROSIS-FACTOR RECEPTOR-BINDING PROTEIN - OPTIMUM BIOLOGICAL-ACTIVITY OF A TRUNCATED P55 SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR IGG FUSION PROTEIN

      European cytokine network
    96. Canada, T
      Focus on infliximab: A TNF-alpha inhibitor that reduces intestinal inflammation in Crohn's disease refractory to conventional therapy

      FORMULARY
    97. BEUTLER B; BAZZONI F
      TNF, APOPTOSIS AND AUTOIMMUNITY - A COMMON THREAD

      Blood cells, molecules, & diseases
    98. REIST CJ; BIGNER DD; ZALUTSKY MR
      HUMAN IGG2 CONSTANT-REGION ENHANCES IN-VIVO STABILITY OF ANTI-TENASCIN ANTIBODY 81C6 COMPARED WITH ITS MURINE PARENT

      Clinical cancer research
    99. NAKADA MT; TAM SH; WOULFE DS; CASPER KA; SWERLICK RA; GHRAYEB J
      NEUTRALIZATION OF TNF BY THE ANTIBODY CA2 REVEALS DIFFERENTIAL REGULATION OF ADHESION MOLECULE EXPRESSION ON TNF-ACTIVATED ENDOTHELIAL-CELLS

      Cell adhesion and communication (Softback)
    100. HODGSON HJF
      PATHOGENESIS OF CROHNS-DISEASE

      Bailliere's clinical gastroenterology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 02:28:18